印尼日惹人群CYP2C9、CYP2C19、CYP2D6和SLCO1B1关键药物基因频率及其精准处方意义
该研究采用探针特异性实时PCR对印尼日惹人群进行CYP2C9、CYP2C19、CYP2D6和SLCO1B1基因分型,检测临床相关变异及拷贝数变异。结果显示CYP2C19*2/*3和CYP2D6*10等位基因频率高,SLCO1B1功能减低变异常见,CYP2C9*3亦可检出,提示需制定区域特异性药物基因组学策略以支持精准处方。
要点
- 日惹人群CYP2C19*2/*3和CYP2D6*10等位基因频率高,与东南亚人群特征一致。
- SLCO1B1功能减低变异常见,提示他汀相关肌病风险升高。
- 检出CYP2C9*3等位基因,提示华法林和非甾体抗炎药处方需谨慎。
核心结论
- 日惹人群CYP2C19*2/*3和CYP2D6*10等位基因频率高,SLCO1B1功能减低变异常见,CYP2C9*3亦可检出。
- 观察到的基因型分布提示印尼需要区域特异性药物基因组学策略。
- 该基础数据集支持精准处方方案开发,并强调将基因分型整合入临床实践以提高治疗安全性和有效性。
研究设计与样本
- 研究采用探针特异性实时PCR平台对印尼日惹人群进行基因分型。
- 检测面板覆盖CYP2C9、CYP2C19、CYP2D6和SLCO1B1的临床相关变异,并在适用时整合SNP和拷贝数变异分析。
主要发现
- CYP2C19*2/*3和CYP2D6*10等位基因频率高,与东南亚人群特征一致。
- SLCO1B1功能减低变异常见,提示他汀诱导肌病风险升高。
- 检出CYP2C9*3等位基因,提示华法林和非甾体抗炎药处方需谨慎。
临床怎么用
- 针对日惹人群高频率的CYP2C19*2/*3和CYP2D6*10,可考虑区域特异性基因分型以指导相关药物处方。
- 对携带SLCO1B1功能减低变异者,处方他汀时需关注肌病风险。
- 检出CYP2C9*3等位基因者,使用华法林和非甾体抗炎药时应谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genetic variations in CYP2C9, CYP2C19, CYP2D6, and SLCO1B1 significantly influence drug metabolism and transport, impacting therapeutic response and adverse event risk. While pharmacogenomic guidelines advocate for genotype-guided therapy, no population-specific frequency data exist for these pharmacogenes in Yogyakarta, Indonesia-a region where medication use and polypharmacy are common. This study aims to determine the allele and genotype frequencies of CYP2C9, CYP2C19, CYP2D6, and SLCO1B1 in the Yogyakarta, Indonesia population to inform regionally appropriate prescribing practices. Genotyping was performed using probe-specific real-time PCR (RT-PCR) platforms. The panel targeted clinically relevant variants across CYP2C9, CYP2C19, CYP2D6, and SLCO1B1, integrating SNP and copy number variant analysis where applicable. High frequencies of CYP2C19 *2/*3 and CYP2D6*10 alleles were observed, consistent with Southeast Asian profiles. SLCO1B1 reduced-function variants were prevalent, suggesting elevated risk for statin-induced myopathy. CYP2C9*3 allele was also detected, warranting caution in warfarin and NSAID prescribing. The observed genotype distributions highlight the need for region-specific pharmacogenomic strategies in Indonesia. This foundational dataset supports the development of precision prescribing protocols and reinforces the importance of integrating genotyping into clinical practice to improve therapeutic safety and effectiveness.
引用
- Nugrahaningsih DAA, Chintyasari S, Wijayaningsih RA, et al. Frequency of Key Pharmacogenes CYP2C9, CYP2C19, CYP2D6, and SLCO1B1 in the Yogyakarta Population: Implications for Precision Prescribing in Indonesia. Clin Pharmacol Ther. 2026. PMID: 42050991. doi:10.1002/cpt.70297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。